Kenneth Westover, MD, PhD, Associate Professor of Radiation Oncology and Biochemistry
Ken Westover is a practicing thoracic radiation oncologist with expertise in structural biology, biochemistry, cancer biology and structure-based drug development. His team, together with collaborators, developed inhibitors to other kinase cancer targets including mTOR, TAK1 and HER3. Additionally, the Westover lab, together with collaborators, developed covalent GTP-competitive inhibitors and quinazoline scaffold switch 2 pocket inhibitors of KRAS G12C, the most common RAS mutation found in lung cancer. Recent work has established a model for RAS dimerization and validated the importance of RAS dimerization for biological function. Finally, multiple efforts are directed at understanding differences in RAS cancer allele-specific mechanisms of activation. Clinically Dr. Westover studies radiation treatments utilizing hypofractionated radiation such as stereotactic body radiation therapy (SBRT).
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Vibliome TherapeuticsTopic:Early stage drug discovery
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AmgenTopic:KRAS G12C inhibitors